Dana-Farber Cancer Institute Partners with OncoHost for Groundbreaking Kidney Cancer Study

Dana-Farber Cancer Institute partners with OncoHost to study biomarkers for renal cell carcinoma, aiming to enhance clinical decision-making and patient management. The study will analyze blood samples to create personalized treatment plans and predict patient responses to immune-checkpoint inhibitor therapy, revolutionizing kidney cancer treatment.